News

Developed by Eli Lilly and Boehringer Ingelheim, the new insulin glargine product is the first biosimilar insulin recommended for approval in the European Union (EU). The new insulin

The inhalation powder in AFREZZA is delivered using a small, discreet and easy-to-use inhaler. The company said that the AFREZZA should be administered at the start of a

According to the company, the CHMP positive opinion of Triumeq (dolutegravir/abacavir/lamivudine) is based upon data from two major studies. The first study is a Phase III trial of

The single-center, randomized withdrawal trial will enrol about 12 PWS patients between 10 and 20 years old. During the trial, patients will be titrated through five doses of

The CHMP’s positive opinion will now be reviewed by the European Commission (EC). The decision on whether to approve Eliquis for this indication will be made by the

KALYDECO was first approved in Europe in July 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation, which

"Diabetes is a growing health concern worldwide and this milestone brings us one step closer to being able to offer patients and physicians in the European Union a

MCL is a rare and aggressive blood cancer that usually occurs in older adults. VELCADE, in combination with other agents, is currently licensed to treat patients with Multiple

TAS-102 achieved statistically significant improvements in overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC) whose disease had progressed after or who